Gilead Sciences set aside $200 million for a potential settlement with federal prosecutors to resolve an investigation into ...
Gilead Sciences Inc. closed 0.11% below its 52-week high of $112.11, which the company reached on February 25th.
Weeks after settling a five-year patent dispute with the U.S. | Gilead set aside approximately $200 million for a potential ...
Oppenheimer raised the firm’s price target on Gilead (GILD) to $132 from $115 and keeps an Outperform rating on the shares. The firm says that ...
Hulu is nearing a series order for 'The Handmaid’s Tale' spinoff 'The Testaments' before the hit show's final season ...
Gilead Sciences' Q4 2024 results, driven by HIV drug demand and Trodelvy growth, make it a compelling choice for long-term ...
The Handmaid’s Tale creator Bruce Miller has reportedly been working on the show for “several years” now, and stepped down as ...
3h
Daily Maverick on MSNThe Global Fund will roll out the twice-yearly anti-HIV jab – with or without PepfarThe Global Fund to Fight AIDS, Tuberculosis and Malaria says it will fund the rollout of the twice-yearly anti-HIV jab, ...
14h
Hosted on MSNThe Handmaid's Tale Sequel Show Casts Its Young Protagonist With A Connection To GileadHulu’s The Testaments casts its Daisy, a Canadian teen whose world is upended when she discovers her hidden connection to ...
Gilead Sciences is rated a Strong Buy due to strong Q4 2024 results and a robust HIV franchise. Check out my 12-month price target for GILD stock.
Under U.S. law, most patents are limited to a term of 20 years from the earliest nonprovisional filing date. However, Patent Term Adjustment (PTA) ...
Hulu’s upcoming series “ The Testaments ,” a sequel to “The Handmaid’s Tale,” has cast Lucy Halliday in the role of Daisy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results